In a report released today, Andrew Cooper from Raymond James maintained a Buy rating on Fulgent Genetics (FLGT – Research Report). The company’s shares closed yesterday at $32.79.
According to TipRanks, Cooper is an analyst with an average return of -15.2% and a 32.11% success rate. Cooper covers the Healthcare sector, focusing on stocks such as Exact Sciences, Hologic, and Myriad Genetics.
The word on The Street in general, suggests a Hold analyst consensus rating for Fulgent Genetics with a $40.00 average price target.
See today’s best-performing stocks on TipRanks >>
FLGT market cap is currently $965.3M and has a P/E ratio of 3.77.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FLGT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fulgent Genetics, Inc. is a technology company, which focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.
Read More on FLGT:
